Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

Sergio M. Borgia*, Janet Dearden, Eric M. Yoshida, Stephen D. Shafran, Ashley Brown, Ziv Ben-Ari, Matthew E. Cramp, Curtis Cooper, Matthew Foxton, Conrado Fernandez Rodriguez, Rafael Esteban, Robert Hyland, Sophia Lu, Brian J. Kirby, Amy Meng, Svetlana Markova, Hadas Dvory-Sobol, Anu O. Osinusi, Rafael Bruck, Javier AmpueroStephen D. Ryder, Kosh Agarwal, Raymond Fox, David Shaw, Shariq Haider, Bernard Willems, Yoav Lurie, Jose Luis Calleja, Edward J. Gane

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

98 Scopus citations

Fingerprint

Dive into the research topics of 'Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis'. Together they form a unique fingerprint.

Medicine & Life Sciences